Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Vicadrostat in Healthy Japanese Males
NCT03608072Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vicadrostat in chronic kidney disease (CKD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Drug-related adverse events. Started Aug 2018; status: completed.
02
Drugs
vicadrostat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03608072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608072.